The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2018 | CLL trial updates: ALLIANCE & iLLUMINATE
Barbara Eichhorst
• 4 Dec 2018
Barbara Eichhorst, MD, of the University Hospital Cologne, Cologne, Germany, discusses the results of major chronic lymphocytic leukemia (CLL) trials from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA. Dr Eichhorst then summarizes what the implications of these trials are in terms of the use of ibrutinib.
